The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.

Many tumor types are associated with genetic changes in the retinoblastoma pathway, leading to hyperactivation of cyclin-dependent kinases and incorrect progression through the cell cycle. Small-molecule cyclin-dependent kinase inhibitors are being developed as therapeutic agents. Of these, flavopiridol and UCN-01 are being explored in cancer patients in phase I and phase II clinical trials, both as single agents and in combination with conventional chemotherapeutic agents. The present article discusses the mechanisms of action of flavopiridol and UCN-01 as well as the outcome of clinical trials with these novel agents.

[1]  Y. Sugiyama,et al.  Physiological Modeling of Altered Pharmacokinetics of a Novel Anticancer Drug, UCN-01 (7-Hydroxystaurosporine), Caused by Slow Dissociation of UCN-01 from Human α1-Acid Glycoprotein , 2000, Pharmaceutical Research.

[2]  A. Senderowicz,et al.  Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials , 2004, Investigational New Drugs.

[3]  E. Sausville,et al.  Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Smythe,et al.  Activation of mammalian Chk1 during DNA replication arrest , 2001, The Journal of cell biology.

[5]  D. Price,et al.  Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo * , 2001, The Journal of Biological Chemistry.

[6]  B. Rollins,et al.  A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  E. Sausville,et al.  Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Maslak,et al.  Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Maccioni,et al.  The protein kinase Cdk5 , 2001 .

[10]  R. Maccioni,et al.  The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. , 2001, European journal of biochemistry.

[11]  E. Sausville,et al.  Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  A. Senderowicz.  Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies , 2001, Leukemia.

[13]  A. Senderowicz,et al.  Small molecule modulators of cyclin-dependent kinases for cancer therapy , 2000, Oncogene.

[14]  E. Sausville,et al.  Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication* , 2000, The Journal of Biological Chemistry.

[15]  E. Vokes,et al.  Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  John Calvin Reed,et al.  Protein Kinase Inhibitors Flavopiridol and 7-hydroxy-staurosporine Down-regulate Antiapoptosis Proteins in B-cell Chronic Lymphocytic Leukemia , 2022 .

[17]  C. Sherr.  The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.

[18]  A. Gescher.  Staurosporine analogues - pharmacological toys or useful antitumour agents? , 2000, Critical reviews in oncology/hematology.

[19]  D. Price.  P-TEFb, a Cyclin-Dependent Kinase Controlling Elongation by RNA Polymerase II , 2000, Molecular and Cellular Biology.

[20]  J. Sarkaria,et al.  The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. , 2000, Cancer research.

[21]  E. Sausville,et al.  Preclinical and clinical development of cyclin-dependent kinase modulators. , 2000, Journal of the National Cancer Institute.

[22]  Edward A. Sausville,et al.  The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01* , 2000, The Journal of Biological Chemistry.

[23]  E. Vokes,et al.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Slingerland,et al.  Deregulation of the cell cycle in cancer. , 2000, Cancer detection and prevention.

[25]  E. Sausville,et al.  Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. , 1999, Cancer research.

[26]  J. Harbour,et al.  Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1 , 1999, Cell.

[27]  E. Sausville,et al.  Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. , 1999, Cancer research.

[28]  J. Sarkaria,et al.  Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. , 1999, Cancer research.

[29]  A. Senderowicz,et al.  Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. , 1999, International journal of oncology.

[30]  S. Mousa,et al.  Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. , 1999, Anticancer Research.

[31]  K. Yamaguchi,et al.  Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01 , 1999, Cancer Chemotherapy and Pharmacology.

[32]  E. Sausville,et al.  UCN-01 Abrogates G2 Arrest through a Cdc2-dependent Pathway That Is Associated with Inactivation of the Wee1Hu Kinase and Activation of the Cdc25C Phosphatase* , 1998, The Journal of Biological Chemistry.

[33]  E. Sausville,et al.  Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. , 1998, The Journal of clinical investigation.

[34]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[35]  S. Steinberg,et al.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  E. Sausville,et al.  Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. , 1998, Cancer research.

[37]  J. Nevins,et al.  Toward an understanding of the functional complexity of the E2F and retinoblastoma families. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[38]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[39]  D. Nettelbeck,et al.  Cell cycle‐independent induction of apoptosis by the anti‐tumor drug flavopiridol in endothelial cells , 1998, International journal of cancer.

[40]  E. Sausville,et al.  Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. , 1998, Blood.

[41]  K. Helin,et al.  Regulation of cell proliferation by the E2F transcription factors. , 1998, Current opinion in genetics & development.

[42]  K. Kohn,et al.  Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. , 1997, Cancer research.

[43]  J. Verweij,et al.  Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  S. Kaufmann,et al.  Antineoplastic Agents: the Importance of Sequence of Administration' , 2022 .

[45]  A. Eastman,et al.  7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[46]  M. Shimizu,et al.  G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. , 1997, Cancer research.

[47]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[48]  E. Sausville,et al.  Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. , 1996, International journal of oncology.

[49]  H. Nakanishi,et al.  Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. , 1996, Oncology.

[50]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[51]  S H Kim,et al.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  E. Sausville,et al.  Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[53]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[54]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[55]  David O. Morgan,et al.  A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase , 1994, Cell.

[56]  E. Sausville,et al.  Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.

[57]  E. Sausville,et al.  Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. , 1994, Molecular pharmacology.

[58]  H. Piwnica-Worms,et al.  Reversible tyrosine phosphorylation and cell cycle control. , 1993, Seminars in cell biology.

[59]  E. Sausville,et al.  Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. , 1993, Biochemical pharmacology.

[60]  David M. Livingston,et al.  Functional interactions of the retinoblastoma protein with mammalian D-type cyclins , 1993, Cell.

[61]  M. Ewen,et al.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. , 1993, Genes & development.

[62]  A. Pardee.  G1 events and regulation of cell proliferation. , 1989, Science.

[63]  I. Takahashi,et al.  UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I. Screening, producing organism and fermentation. , 1989, The Journal of antibiotics.

[64]  I. Takahashi,et al.  UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. , 1989, The Journal of antibiotics.

[65]  I. Takahashi,et al.  UCN-01, a selective inhibitor of protein kinase C from Streptomyces. , 1987, The Journal of antibiotics.